New VEGF Biomarker Data Illustrates Complexities of Personalizing Anti-Angiogenic Drugs
September 28, 2011
New VEGF Biomarker Data Illustrates Complexities of Personalizing Anti-Angiogenic Drugs
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter - FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data
March 2, 2011 / Pharmacogenomics Reporter - Ventana's Growing Companion Dx Focus Mirrors Parent Roche's Investment in Personalized Rx
January 18, 2012 / Pharmacogenomics Reporter